Proportion of Revertant Samples Among All Positive Stool Samples Collected in 42 Days From Vaccination, by Polio Serotype, Time from the Last Prestool Oral Poliovirus Vaccine Dose, and Human Immunodeficiency Virus Status
A. OPV-1
| . | . | All Positive Samples by Time from OPV . | All Positive Samples Collected in 42 Days from OPV . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | ≤3 Days from Vaccination . | 4–21 Days from Vaccination . | 22–42 Days from Vaccination . | All Records . | One Record per Infant . | ||||||
| . | . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N . | % Revertant . | N^ . | % Revertant . | P Value . |
| OPV naive (1 dose) | HIV– | 5 (17) | 0 | 3 (10) | 0 | 22 (73) | 9 | 30 | 7 | 30 | 7 | 1 |
| HIV+ | 0 (0) | … | 4 (57) | 0 | 3 (43) | 0 | 7 | 0 | 7 | 0 | ||
| OPV exposed (≥2 doses) | HIV– | 32 (40) | 16 | 32 (40) | 9 | 16 (20) | 31 | 80 | 16 | 73 | 18 | .2 |
| HIV+ | 3 (23) | 0 | 3 (23) | 0 | 7 (54) | 0 | 13 | 0 | 11 | 0 | ||
| All | HIV– | 37 (34) | 14 | 35 (32) | 9 | 38 (35) | 18 | 110 | 14 | 101 | 14 | .2 |
| HIV+ | 3 (15) | 0 | 7 (35) | 0 | 10 (50) | 0 | 20 | 0 | 17 | 0 | ||
| . | . | All Positive Samples by Time from OPV . | All Positive Samples Collected in 42 Days from OPV . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | ≤3 Days from Vaccination . | 4–21 Days from Vaccination . | 22–42 Days from Vaccination . | All Records . | One Record per Infant . | ||||||
| . | . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N . | % Revertant . | N^ . | % Revertant . | P Value . |
| OPV naive (1 dose) | HIV– | 5 (17) | 0 | 3 (10) | 0 | 22 (73) | 9 | 30 | 7 | 30 | 7 | 1 |
| HIV+ | 0 (0) | … | 4 (57) | 0 | 3 (43) | 0 | 7 | 0 | 7 | 0 | ||
| OPV exposed (≥2 doses) | HIV– | 32 (40) | 16 | 32 (40) | 9 | 16 (20) | 31 | 80 | 16 | 73 | 18 | .2 |
| HIV+ | 3 (23) | 0 | 3 (23) | 0 | 7 (54) | 0 | 13 | 0 | 11 | 0 | ||
| All | HIV– | 37 (34) | 14 | 35 (32) | 9 | 38 (35) | 18 | 110 | 14 | 101 | 14 | .2 |
| HIV+ | 3 (15) | 0 | 7 (35) | 0 | 10 (50) | 0 | 20 | 0 | 17 | 0 | ||
^Multiple samples from the same infant: HIV–: 7 with 2 samples, 1 with 3 samples; HIV+: 3 with 2 samples.
a Percent of all samples collected in 42 days from vaccination.
Proportion of Revertant Samples Among All Positive Stool Samples Collected in 42 Days From Vaccination, by Polio Serotype, Time from the Last Prestool Oral Poliovirus Vaccine Dose, and Human Immunodeficiency Virus Status
A. OPV-1
| . | . | All Positive Samples by Time from OPV . | All Positive Samples Collected in 42 Days from OPV . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | ≤3 Days from Vaccination . | 4–21 Days from Vaccination . | 22–42 Days from Vaccination . | All Records . | One Record per Infant . | ||||||
| . | . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N . | % Revertant . | N^ . | % Revertant . | P Value . |
| OPV naive (1 dose) | HIV– | 5 (17) | 0 | 3 (10) | 0 | 22 (73) | 9 | 30 | 7 | 30 | 7 | 1 |
| HIV+ | 0 (0) | … | 4 (57) | 0 | 3 (43) | 0 | 7 | 0 | 7 | 0 | ||
| OPV exposed (≥2 doses) | HIV– | 32 (40) | 16 | 32 (40) | 9 | 16 (20) | 31 | 80 | 16 | 73 | 18 | .2 |
| HIV+ | 3 (23) | 0 | 3 (23) | 0 | 7 (54) | 0 | 13 | 0 | 11 | 0 | ||
| All | HIV– | 37 (34) | 14 | 35 (32) | 9 | 38 (35) | 18 | 110 | 14 | 101 | 14 | .2 |
| HIV+ | 3 (15) | 0 | 7 (35) | 0 | 10 (50) | 0 | 20 | 0 | 17 | 0 | ||
| . | . | All Positive Samples by Time from OPV . | All Positive Samples Collected in 42 Days from OPV . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | ≤3 Days from Vaccination . | 4–21 Days from Vaccination . | 22–42 Days from Vaccination . | All Records . | One Record per Infant . | ||||||
| . | . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N (%)a . | % Revertant . | N . | % Revertant . | N^ . | % Revertant . | P Value . |
| OPV naive (1 dose) | HIV– | 5 (17) | 0 | 3 (10) | 0 | 22 (73) | 9 | 30 | 7 | 30 | 7 | 1 |
| HIV+ | 0 (0) | … | 4 (57) | 0 | 3 (43) | 0 | 7 | 0 | 7 | 0 | ||
| OPV exposed (≥2 doses) | HIV– | 32 (40) | 16 | 32 (40) | 9 | 16 (20) | 31 | 80 | 16 | 73 | 18 | .2 |
| HIV+ | 3 (23) | 0 | 3 (23) | 0 | 7 (54) | 0 | 13 | 0 | 11 | 0 | ||
| All | HIV– | 37 (34) | 14 | 35 (32) | 9 | 38 (35) | 18 | 110 | 14 | 101 | 14 | .2 |
| HIV+ | 3 (15) | 0 | 7 (35) | 0 | 10 (50) | 0 | 20 | 0 | 17 | 0 | ||
^Multiple samples from the same infant: HIV–: 7 with 2 samples, 1 with 3 samples; HIV+: 3 with 2 samples.
a Percent of all samples collected in 42 days from vaccination.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
